Corbus Pharmaceuticals Holdings (CRBP) Total Debt (2013 - 2024)

Corbus Pharmaceuticals Holdings has reported Total Debt for 12 years, with the latest figure at $10.8 million in Q2 2024.

• On a quarterly basis, Total Debt fell 41.15% year-over-year to $10.8 million in Q2 2024; TTM through Jun 2024 was $10.8 million, a 41.15% decrease from a year earlier, with the FY2023 full-year figure at $32.1 million, up 67.86% from the prior year.
• Total Debt was $10.8 million for Q2 2024 at Corbus Pharmaceuticals Holdings, down from $13.0 million in the prior quarter.
• The five-year high for Total Debt was $32.1 million in Q4 2023, with the low at $108936.0 in Q2 2020.
• Average Total Debt over 5 years is $16.8 million, with a median of $18.9 million recorded in 2020.
• The sharpest annual moves came in 2021 and 2024: Total Debt soared 17315.82% in 2021, then plunged 41.15% in 2024.
• Over 5 years, Total Debt stood at $18.8 million in 2020, then climbed by 3.57% to $19.5 million in 2021, then retreated by 1.87% to $19.1 million in 2022, then jumped by 67.86% to $32.1 million in 2023, then sank by 66.31% to $10.8 million in 2024.
• The last three Total Debt figures came in at $10.8 million (Q2 2024), $13.0 million (Q1 2024), and $32.1 million (Q4 2023), per Business Quant data.